Dr. David Camidge is a medical oncologist specializing in thoracic oncology and developmental therapeutics. He serves as Director of Thoracic Oncology and Professor of Medicine at the University of Colorado School of Medicine. Clinically, he focuses on thoracic oncology care, precision and targeted therapies, and early-phase clinical trials. His research centers on developmental therapeutics, immuno-oncology, and biomarker-driven early-phase trial design in thoracic malignancies. He is the National Medical Director of the Academic Thoracic Oncology Medical Investigators Consortium and has contributed to national guideline development as a past member of multiple NCCN thoracic committees. A recognized leader in the field, he has been named a Clarivate Highly Cited Researcher, recognized by Expertscape as a world expert, and honored with awards including the Bonnie J. Addario Lectureship Award, the Hank Baskett Sr. Spirit Award, the Breath Away from the Cure Award, and institutional distinctions for mentorship and exceptional clinical care. He holds the Inaugural Joyce Zeff Chair in Lung Cancer Research at the University of Colorado Cancer Center. Dr. Camidge earned his medical degree from the University of Oxford, completed a PhD in molecular biology at the University of Cambridge, and was the first physician in the United Kingdom to complete dual training in medical oncology and clinical pharmacology.
Professor
Medical School
1995
Residency
1995 – 1995